ライフサイエンスコーパス: antithrombotic drug

1 s and to test the efficacy and safety of new antithrombotic drugs.

2 n their antithrombotic effects than previous antithrombotic drugs.

3 intraocular bleeding between NOACs and other antithrombotic drugs.

4 CH, provoking uncertainties about the use of antithrombotic drugs.

5 r (VWF) is a promising target for developing antithrombotic drugs.

6 ly more vulnerable to the adverse effects of antithrombotic drugs.

7 cial for developing safer and more effective antithrombotic drugs.

8 e potential targets for development of novel antithrombotic drugs.

9 ate, and annual prevalence of treatment with antithrombotic drugs.

10 1.07 to 2.04; p = 0.02), and use of multiple antithrombotic drugs (adjusted HR: 1.33; 95% CI: 1.14 to

11 ife AF patients with indication for multiple antithrombotic drugs after MI/PCI, OAC and clopidogrel w

12 of lipid-lowering, blood pressure-lowering, antithrombotic drugs and diet and their place in the pre

13 iography and assessed their association with antithrombotic drugs and mortality risk.

14 To estimate the association between use of antithrombotic drugs and subdural hematoma risk and dete

15 Increased knowledge of the pharmacology of antithrombotic drugs and the mechanisms underlying throm

16 properties of these most commonly used oral antithrombotic drugs, and explore the development of ant

17 , differences exist in the safety profile of antithrombotic drugs, and little is known about their in

18 Many antithrombotic drugs are eliminated mainly by the kidney

19 Antithrombotic drugs are used after coronary-artery sten

20 mechanobiology, and holds great potential in antithrombotic drug development and assessing platelet a

21 ould be a candidate or lead compound for new antithrombotic drug development.

22 retically interesting therapeutic target for antithrombotic drugs for many years.

23 Antiplatelet and antithrombotic drugs form the bedrock of management of p

24 Current antithrombotic drugs have an adverse effect on bleeding,

25 usion of more severe strokes, greater use of antithrombotic drugs, higher doses, and the longer time

26 ggest that A1-A1 could be a prototype for an antithrombotic drug in APS.

27 However, the lack of data on new antithrombotic drugs including GII/GIIIA antagonists, fa

28 An antithrombotic drug is needed that safely reduces cardio

29 extent this is related to increasing use of antithrombotic drugs is unknown.

30 Newly approved antithrombotic drugs maintain the need for updated revie

31 pled P2Y purinoceptor 12, as an antiplatelet/antithrombotic drug, our data suggest that specifically

32 s to be associated with the increased use of antithrombotic drugs, particularly use of a VKA among ol

33 We compared the efficacy and safety of three antithrombotic-drug regimens - aspirin alone, aspirin an

34 imal use of combinations of antiplatelet and antithrombotic drugs requires improved methods for asses

35 eceptors are the targets of very widely used antithrombotic drugs such as clopidogrel, prasugrel, and

36 ctivation and thereby serves as an important antithrombotic drug target.

37 aggregation, and thus serves as an important antithrombotic drug target.

38 regulator of platelet activation and a novel antithrombotic drug target.

39 surface of platelets and that it could be an antithrombotic drug target.

40 tivation and thrombus formation, and several antithrombotic drugs targeting P2Y12R--including the pro

41 eed for new molecular targets for developing antithrombotic drugs that minimally affect hemostasis.

42 ncreased bleeding and the development of new antithrombotic drugs, the use of alphaIIbbeta3 antagonis

43 P2Y(12) is the target of antithrombotic drugs (ticlopidine, clopidogrel), whereas

44 Upstream administration of antithrombotic drugs to patients with non-ST-segment ele

45 -1 (ICAM-1) targeting is suitable to deliver antithrombotic drugs to the pulmonary vascular lumen.

46 ), a direct oral anticoagulant, and combined antithrombotic drug treatment.

47 ne trends in subdural hematoma incidence and antithrombotic drug use in the general population.

48 The prevalence of antithrombotic drug use increased from 31.0 per 1000 ind

49 In Denmark, antithrombotic drug use was associated with higher risk

50 Subdural hematoma incidence and antithrombotic drug use was identified using population-

51 Association of subdural hematoma with antithrombotic drug use, subdural hematoma incidence rat

52 Treatment with any antithrombotic drug was comparable in the 2 groups (76.8

53 Antithrombotic drugs, which include antiplatelet and ant

54 represents a potential target for developing antithrombotic drugs with minimal bleeding side effect.

55 discovery of new orthosteric and allosteric antithrombotic drugs with reduced adverse effects.

56 artly explained by differences in the use of antithrombotic drugs within the first 24 h of thrombolys